Efficacy & safety of fast-acting insulin aspart are maintained over 52 weeks: comparison with insulin aspart in onset 1
Keyword(s):
Keyword(s):
2019 ◽
Vol 21
(9)
◽
pp. 2039-2047
◽
Keyword(s):
2019 ◽
Vol 59
(2)
◽
pp. 155-172
◽
2017 ◽
Vol 37
(5)
◽
pp. 503-509
◽
Keyword(s):
Keyword(s):